Alto Neuroscience (NYSE:ANRO) Price Target Raised to $22.00

Alto Neuroscience (NYSE:ANRO) had its price target boosted by Wedbush from $13.00 to $22.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Other analysts also recently issued research reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Alto Neuroscience in a research report on Monday, December 29th. Chardan Capital reaffirmed a “buy” rating and issued a $30.00 price target on shares of Alto Neuroscience in a report on Tuesday. BTIG Research raised their price objective on shares of Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $35.00 target price on shares of Alto Neuroscience in a research report on Monday. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.33.

Alto Neuroscience Stock Down 2.2%

Shares of NYSE ANRO opened at $22.02 on Tuesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.42 and a current ratio of 15.69. Alto Neuroscience has a 1 year low of $1.60 and a 1 year high of $25.17. The stock’s 50-day simple moving average is $18.37 and its 200-day simple moving average is $13.47. The firm has a market cap of $703.44 million, a price-to-earnings ratio of -10.10 and a beta of 2.52.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. As a group, equities analysts anticipate that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

Institutional investors have recently modified their holdings of the business. Vestal Point Capital LP raised its stake in Alto Neuroscience by 161.6% during the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after acquiring an additional 1,535,000 shares during the period. Commodore Capital LP bought a new position in shares of Alto Neuroscience during the fourth quarter valued at approximately $32,453,000. Perceptive Advisors LLC grew its holdings in shares of Alto Neuroscience by 1,048.5% during the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after purchasing an additional 1,629,027 shares during the last quarter. Armistice Capital LLC raised its position in shares of Alto Neuroscience by 0.7% during the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after purchasing an additional 12,000 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of Alto Neuroscience by 1.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,105,407 shares of the company’s stock worth $4,444,000 after purchasing an additional 20,702 shares during the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.